Literature DB >> 18285838

Smith-Lemli-Opitz syndrome: pathogenesis, diagnosis and management.

Forbes D Porter1.   

Abstract

Smith-Lemli-Opitz syndrome (SLOS) is a malformation syndrome due to a deficiency of 7-dehydrocholesterol reductase (DHCR7). DHCR7 primarily catalyzes the reduction of 7-dehydrocholesterol (7DHC) to cholesterol. In SLOS, this results in decreased cholesterol and increased 7DHC levels, both during embryonic development and after birth. The malformations found in SLOS may result from decreased cholesterol, increased 7DHC or a combination of these two factors. This review discusses the clinical aspects and diagnosis of SLOS, therapeutic interventions and the current understanding of pathophysiological processes involved in SLOS.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18285838     DOI: 10.1038/ejhg.2008.10

Source DB:  PubMed          Journal:  Eur J Hum Genet        ISSN: 1018-4813            Impact factor:   4.246


  98 in total

Review 1.  Malformation syndromes caused by disorders of cholesterol synthesis.

Authors:  Forbes D Porter; Gail E Herman
Journal:  J Lipid Res       Date:  2010-10-07       Impact factor: 5.922

2.  Cholesterol auxotrophy and intolerance to ezetimibe in mice with SREBP-2 deficiency in the intestine.

Authors:  Shunxing Rong; Jeffrey G McDonald; Luke J Engelking
Journal:  J Lipid Res       Date:  2017-06-19       Impact factor: 5.922

3.  Pulmonary vein stenosis in patients with Smith-Lemli-Opitz syndrome.

Authors:  Aaron R Prosnitz; Jane Leopold; Mira Irons; Kathy Jenkins; Amy E Roberts
Journal:  Congenit Heart Dis       Date:  2017-07-18       Impact factor: 2.007

4.  Disruption of Dhcr7 and Insig1/2 in cholesterol metabolism causes defects in bone formation and homeostasis through primary cilium formation.

Authors:  Akiko Suzuki; Kenichi Ogata; Hiroki Yoshioka; Junbo Shim; Christopher A Wassif; Forbes D Porter; Junichi Iwata
Journal:  Bone Res       Date:  2020-01-02       Impact factor: 13.567

5.  Nanostructure-initiator mass spectrometry (NIMS) imaging of brain cholesterol metabolites in Smith-Lemli-Opitz syndrome.

Authors:  G J Patti; L P Shriver; C A Wassif; H K Woo; W Uritboonthai; J Apon; M Manchester; F D Porter; G Siuzdak
Journal:  Neuroscience       Date:  2010-07-27       Impact factor: 3.590

6.  Analysis of short-term behavioral effects of dietary cholesterol supplementation in Smith-Lemli-Opitz syndrome.

Authors:  Elaine Tierney; Sandra K Conley; Halima Goodwin; Forbes D Porter
Journal:  Am J Med Genet A       Date:  2010-01       Impact factor: 2.802

Review 7.  The function of G-protein coupled receptors and membrane cholesterol: specific or general interaction?

Authors:  Yamuna Devi Paila; Amitabha Chattopadhyay
Journal:  Glycoconj J       Date:  2008-12-04       Impact factor: 2.916

8.  Unraveling the disease pathogenesis behind lethal hydrolethalus syndrome revealed multiple changes in molecular and cellular level.

Authors:  Heli Honkala; Jenni Lahtela; Heli Fox; Massimiliano Gentile; Niklas Pakkasjärvi; Riitta Salonen; Kirmo Wartiovaara; Matti Jauhiainen; Marjo Kestilä
Journal:  Pathogenetics       Date:  2009-04-28

9.  Causes of death and associated conditions (Codac): a utilitarian approach to the classification of perinatal deaths.

Authors:  J Frederik Frøen; Halit Pinar; Vicki Flenady; Safiah Bahrin; Adrian Charles; Lawrence Chauke; Katie Day; Charles W Duke; Fabio Facchinetti; Ruth C Fretts; Glenn Gardener; Kristen Gilshenan; Sanne J Gordijn; Adrienne Gordon; Grace Guyon; Catherine Harrison; Rachel Koshy; Robert C Pattinson; Karin Petersson; Laurie Russell; Eli Saastad; Gordon C S Smith; Rozbeh Torabi
Journal:  BMC Pregnancy Childbirth       Date:  2009-06-10       Impact factor: 3.007

10.  Induction of a massive endoplasmic reticulum and perinuclear space expansion by expression of lamin B receptor mutants and the related sterol reductases TM7SF2 and DHCR7.

Authors:  Monika Zwerger; Thorsten Kolb; Karsten Richter; Iakowos Karakesisoglou; Harald Herrmann
Journal:  Mol Biol Cell       Date:  2009-11-25       Impact factor: 4.138

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.